JP2016507066A - 多発性骨髄腫、慢性リンパ球性白血病、およびｂ細胞非ホジキンリンパ腫の改善された診断方法、予後予測方法、およびモニタリング方法 - Google Patents

多発性骨髄腫、慢性リンパ球性白血病、およびｂ細胞非ホジキンリンパ腫の改善された診断方法、予後予測方法、およびモニタリング方法 Download PDF

Info

Publication number
JP2016507066A
JP2016507066A JP2015557128A JP2015557128A JP2016507066A JP 2016507066 A JP2016507066 A JP 2016507066A JP 2015557128 A JP2015557128 A JP 2015557128A JP 2015557128 A JP2015557128 A JP 2015557128A JP 2016507066 A JP2016507066 A JP 2016507066A
Authority
JP
Japan
Prior art keywords
fragment
biological sample
bcma
subject
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2015557128A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016507066A5 (OSRAM
Inventor
ジェイムズ アール． ベレンソン，
ジェイムズ アール． ベレンソン，
ハイミン チェン，
ハイミン チェン，
エリック サンチェス，
エリック サンチェス，
Original Assignee
インスティテュート フォー ミエローマ アンド ボーン キャンサー リサーチ
インスティテュート フォー ミエローマ アンド ボーン キャンサー リサーチ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インスティテュート フォー ミエローマ アンド ボーン キャンサー リサーチ, インスティテュート フォー ミエローマ アンド ボーン キャンサー リサーチ filed Critical インスティテュート フォー ミエローマ アンド ボーン キャンサー リサーチ
Publication of JP2016507066A publication Critical patent/JP2016507066A/ja
Publication of JP2016507066A5 publication Critical patent/JP2016507066A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7151—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF]; for lymphotoxin [LT]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
JP2015557128A 2013-02-08 2014-02-07 多発性骨髄腫、慢性リンパ球性白血病、およびｂ細胞非ホジキンリンパ腫の改善された診断方法、予後予測方法、およびモニタリング方法 Withdrawn JP2016507066A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361762753P 2013-02-08 2013-02-08
US61/762,753 2013-02-08
PCT/US2014/015338 WO2014124280A1 (en) 2013-02-08 2014-02-07 Improved diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and b-cell non-hodgkin lymphoma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018090456A Division JP2018136344A (ja) 2013-02-08 2018-05-09 多発性骨髄腫、慢性リンパ球性白血病、およびｂ細胞非ホジキンリンパ腫の改善された診断方法、予後予測方法、およびモニタリング方法

Publications (2)

Publication Number Publication Date
JP2016507066A true JP2016507066A (ja) 2016-03-07
JP2016507066A5 JP2016507066A5 (OSRAM) 2017-03-09

Family

ID=51300158

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015557128A Withdrawn JP2016507066A (ja) 2013-02-08 2014-02-07 多発性骨髄腫、慢性リンパ球性白血病、およびｂ細胞非ホジキンリンパ腫の改善された診断方法、予後予測方法、およびモニタリング方法
JP2018090456A Pending JP2018136344A (ja) 2013-02-08 2018-05-09 多発性骨髄腫、慢性リンパ球性白血病、およびｂ細胞非ホジキンリンパ腫の改善された診断方法、予後予測方法、およびモニタリング方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018090456A Pending JP2018136344A (ja) 2013-02-08 2018-05-09 多発性骨髄腫、慢性リンパ球性白血病、およびｂ細胞非ホジキンリンパ腫の改善された診断方法、予後予測方法、およびモニタリング方法

Country Status (5)

Country Link
US (2) US10126301B2 (OSRAM)
EP (1) EP2954330A4 (OSRAM)
JP (2) JP2016507066A (OSRAM)
CA (1) CA2900529A1 (OSRAM)
WO (1) WO2014124280A1 (OSRAM)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10126301B2 (en) 2013-02-08 2018-11-13 Institute For Myeloma & Bone Cancer Research Diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and B-cell non-hodgkin lymphoma
EP3368903A1 (en) * 2015-10-30 2018-09-05 GlaxoSmithKline Intellectual Property Development Limited Prognostic method
ES2898329T3 (es) * 2016-01-12 2022-03-07 Oncotracker Inc Métodos mejorados para supervisar el estado inmunitario de un sujeto
WO2017201040A1 (en) 2016-05-16 2017-11-23 Berenson James Richard Improved methods for monitoring immune status of a subject
WO2018151836A1 (en) 2017-02-17 2018-08-23 Fred Hutchinson Cancer Research Center Combination therapies for treatment of bcma-related cancers and autoimmune disorders
WO2018160553A1 (en) * 2017-02-28 2018-09-07 Menarini Silicon Biosystems, Inc. Improved kits and assays to detect circulating multiple myeloma cells from blood
WO2018231944A1 (en) 2017-06-13 2018-12-20 Berenson James R Diagnostic, prognostic, and monitoring methods for solid tumor cancers
ES2644580B2 (es) * 2017-07-26 2018-06-04 Universitat Politècnica De València Procedimiento de diagnóstico de lupus eritematoso sistémico (les)
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
MX2020004568A (es) 2017-11-06 2020-10-05 Juno Therapeutics Inc Combinación de una terapia celular y un inhibidor de gamma secretasa.
WO2019139987A1 (en) 2018-01-09 2019-07-18 Elstar Therapeutics, Inc. Calreticulin binding constructs and engineered t cells for the treatment of diseases
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
EP3802611A2 (en) 2018-06-01 2021-04-14 Novartis AG Binding molecules against bcma and uses thereof
CN112955465A (zh) 2018-07-03 2021-06-11 马伦戈治疗公司 抗tcr抗体分子及其用途
EP3844503B1 (en) * 2018-08-31 2024-05-29 F. Hoffmann-La Roche AG Thymidine kinase (tk-1) in prognostic indices for dlbcl
WO2020172605A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Antibody molecules that bind to nkp30 and uses thereof
JP7710373B2 (ja) 2019-02-21 2025-07-18 マレンゴ・セラピューティクス，インコーポレーテッド Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用
CU20210096A7 (es) 2019-05-21 2022-06-06 Novartis Ag Moléculas de unión a cd19
CA3166629A1 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
US20250099579A1 (en) 2021-04-08 2025-03-27 Marengo Therapeutics, Inc. Multispecific molecules binding to tcr and uses thereof
CN117305458B (zh) * 2023-10-20 2024-06-21 四川省医学科学院·四川省人民医院 TKTmRNA检测试剂在制备多发性骨髓瘤筛查试剂盒中的用途及试剂盒

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070207474A1 (en) * 2005-11-01 2007-09-06 Ansell Stephen M PROMOTER POLYMORPHISMS OF THE BLyS GENE AND USE IN DIAGNOSTIC METHODS
WO2012143498A1 (en) * 2011-04-21 2012-10-26 Boehringer Ingelheim International Gmbh Bcma-based stratification and therapy for multiple myeloma patients
WO2012163805A1 (en) * 2011-05-27 2012-12-06 Glaxo Group Limited Bcma (cd269/tnfrsf17) -binding proteins

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4493795A (en) 1983-10-17 1985-01-15 Syntex (U.S.A.) Inc. Synthetic peptide sequences useful in biological and pharmaceutical applications and methods of manufacture
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US6383480B1 (en) 1996-07-10 2002-05-07 Meiji Milk Products, Co., Ltd. Composition comprising midkine or pleiotrophin protein and method of increasing hematopoietic cells
GB9704444D0 (en) * 1997-03-04 1997-04-23 Isis Innovation Non-invasive prenatal diagnosis
US6355623B2 (en) * 1998-09-24 2002-03-12 Hopital-Sainte-Justine Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage
US20040002068A1 (en) * 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US7320991B2 (en) 2001-02-27 2008-01-22 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health Analogs of thalidomide as potential angiogenesis inhibitors
AU2002339901A2 (en) 2001-09-06 2003-03-24 Biogen Idec Ma Inc. Crystal structure of baff, and use thereof in drug design
CA2523776A1 (en) 2003-03-07 2004-09-23 Xencor, Inc. Baff mutants with at least one amino acid substitution and methods of their production
JP5570681B2 (ja) 2004-08-31 2014-08-13 興和株式会社 抗ヒトｂａｆｆ抗体
EP2332563A3 (en) 2004-10-13 2013-03-13 The Washington University Use of BAFF to treat sepsis
CA2590461A1 (en) 2004-12-23 2006-06-29 Laboratoires Serono S.A. Bcma polypeptides and uses thereof
US8609821B2 (en) * 2005-09-26 2013-12-17 Enzo Therapeutics, Inc. Antibodies against APRIL as biomarkers for early prognosis of lymphoma patients
WO2007056288A2 (en) * 2005-11-08 2007-05-18 Biogen Idec Ma Inc. Methods of evaluating baff
ES2618543T3 (es) 2005-11-23 2017-06-21 Genentech, Inc. Métodos y composiciones relacionados con ensayos de linfocitos B
PT1966202E (pt) 2005-12-13 2012-01-03 Incyte Corp Pirrolo[2,3-b] pirimidinas e pirrolo[2,3-b]piridinas substituídas com heteroarilo como inibidores de janus quinase
CA2644136A1 (en) 2006-02-27 2007-09-07 The Johns Hopkins University Cancer treatment with gamma-secretase inhibitors
DK2016102T3 (da) 2006-05-03 2012-07-02 Us Gov Health & Human Serv Kimære T-cellereceptorer og tilhørende materialer og fremgangsmåder til anvendelse
RS53245B2 (sr) 2007-06-13 2022-10-31 Incyte Holdings Corp Soli inhibitora janus kinaze (r)-3-(4-(7h-pirolo(2,3-d) pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopentilpropan-nitrila
CA2720682A1 (en) 2008-04-25 2009-10-29 Zymogenetics, Inc. Levels of bcma protein expression on b cells and use in diagnostic methods
NZ594985A (en) 2009-03-10 2013-07-26 Biogen Idec Inc Anti-bcma (b-cell maturation antigen, cd269, tnfrsf17) antibodies
US9101559B2 (en) 2009-05-08 2015-08-11 New York University Leukemic cell CNS infiltration controlled by notch-induced chemotaxis
AU2013340799B2 (en) 2012-11-01 2018-08-09 Max-Delbruck-Centrum Fur Molekulare Medizin (Mdc) An antibody that binds CD269 (BCMA) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
EP2762496A1 (en) 2013-02-05 2014-08-06 EngMab AG Method for the selection of antibodies against BCMA
US10126301B2 (en) 2013-02-08 2018-11-13 Institute For Myeloma & Bone Cancer Research Diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and B-cell non-hodgkin lymphoma
JP2017503001A (ja) 2014-01-20 2017-01-26 ギリアード サイエンシーズ， インコーポレイテッド がんを処置するための療法
KR102632731B1 (ko) 2014-04-30 2024-02-01 막스-델부뤽-센트럼 퓌어 몰레쿨라레 메디친 인 데어 헬름홀츠-게마인샤프트 Ｃｄ269에 대한 인간화 항체
EP4233870A3 (en) 2014-05-28 2024-01-24 Onco Tracker, Inc. Anti-cancer effects of jak2 inhibitors in combination with thalidomide derivatives and glucocorticoids
WO2015191668A1 (en) 2014-06-10 2015-12-17 Institute For Myeloma & Bone Cancer Research Anti-cancer effects of proteasome inhibitors in combination with glucocorticoids, arsenic containing compounds, and ascorbic acid
DK3179992T3 (da) 2014-08-11 2022-07-11 Acerta Pharma Bv Terapeutisk kombination af en btk-inhibitor, en pd-1-inhibitor og/eller en pd-l1-inhibitor
EP3206711B1 (en) 2014-10-14 2023-05-31 Novartis AG Antibody molecules to pd-l1 and uses thereof
EP3227432B1 (en) 2014-12-05 2023-10-11 Memorial Sloan Kettering Cancer Center Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
ES2883249T3 (es) 2015-03-17 2021-12-07 Mayo Found Medical Education & Res Métodos y materiales para evaluar y tratar el cáncer
HK1255694A1 (zh) 2015-07-24 2019-08-23 Oncotracker, Inc. 用於治疗免疫系统功能障碍的γ分泌酶调节剂
UA127515C2 (uk) 2015-08-17 2023-09-20 Янссен Байотек, Інк. Антитіло до всма, біспецифічна антигензв'язувальна молекула, що зв'язує всма і cd3, і їх використання
EP3368903A1 (en) 2015-10-30 2018-09-05 GlaxoSmithKline Intellectual Property Development Limited Prognostic method
ES2898329T3 (es) 2016-01-12 2022-03-07 Oncotracker Inc Métodos mejorados para supervisar el estado inmunitario de un sujeto
WO2017201040A1 (en) 2016-05-16 2017-11-23 Berenson James Richard Improved methods for monitoring immune status of a subject
JP2019527696A (ja) 2016-08-01 2019-10-03 ノバルティス アーゲー プロｍ２マクロファージ分子の阻害剤と組み合わせてキメラ抗原受容体を用いる癌の処置
WO2018085363A2 (en) 2016-11-02 2018-05-11 Berenson James Richard Cd147 detection in diagnostic, prognostic and monitoring methods for multiple myeloma
WO2018231944A1 (en) 2017-06-13 2018-12-20 Berenson James R Diagnostic, prognostic, and monitoring methods for solid tumor cancers
US12036241B2 (en) 2017-07-19 2024-07-16 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
EP3873478A4 (en) 2018-10-31 2022-08-10 Oncotracker, Inc. METHOD OF IMPROVING IMMUNE-BASED THERAPY

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070207474A1 (en) * 2005-11-01 2007-09-06 Ansell Stephen M PROMOTER POLYMORPHISMS OF THE BLyS GENE AND USE IN DIAGNOSTIC METHODS
WO2012143498A1 (en) * 2011-04-21 2012-10-26 Boehringer Ingelheim International Gmbh Bcma-based stratification and therapy for multiple myeloma patients
WO2012163805A1 (en) * 2011-05-27 2012-12-06 Glaxo Group Limited Bcma (cd269/tnfrsf17) -binding proteins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ERIC SANCHEZ,ET AL.: "Serum B-cell maturation antigen is elevated in multiole myeloma and correlates with disease status a", BRITISH JOURNAL OF HAEMATOLOGY, vol. Volume 158, Issue 6, JPN7017003662, 18 July 2012 (2012-07-18), pages 727 - 738, ISSN: 0003679709 *
JEROME MOREAUX,ET AL.: "BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamet", BLOOD, vol. VOLUME 103,NUMBER 8, JPN7017003663, 15 April 2004 (2004-04-15), pages 3147 - 3157, ISSN: 0003679710 *

Also Published As

Publication number Publication date
US20160131654A1 (en) 2016-05-12
CA2900529A1 (en) 2014-08-14
EP2954330A1 (en) 2015-12-16
US12174189B2 (en) 2024-12-24
JP2018136344A (ja) 2018-08-30
WO2014124280A1 (en) 2014-08-14
US20190107541A1 (en) 2019-04-11
EP2954330A4 (en) 2016-08-31
US10126301B2 (en) 2018-11-13

Similar Documents

Publication Publication Date Title
US12174189B2 (en) Diagnostic, prognostic, and monitoring methods for chronic lymphocytic leukemia
JP2022058619A (ja) 被験体の免疫状態をモニタリングするための改善された方法
EP3458853B1 (en) Improved methods for monitoring immune status of a subject
EP3639028B1 (en) Diagnostic, prognostic, and monitoring methods for breast cancer
EP2551673B1 (en) Methods for the detection of cancer infiltration of the central nervous system
CN107615071B (zh) 用于包含乐伐替尼和依维莫司的联合疗法的生物标志
ES2939143T3 (es) Biomarcadores para una politerapia que comprende lenvatinib y everolimus
WO2018085363A2 (en) Cd147 detection in diagnostic, prognostic and monitoring methods for multiple myeloma
HK40082699A (en) Improved methods for monitoring immune status of a subject
CA3010019C (en) Improved methods for monitoring immune status of a subject
EP3832309A1 (en) Composition for diagnosis of bone metastasis of cancer and kit comprising same
HK40000182B (en) Improved methods for monitoring immune status of a subject
HK40007456B (en) Improved methods for monitoring immune status of a subject
HK40007456A (en) Improved methods for monitoring immune status of a subject
KR101567053B1 (ko) 방사선 피폭에 의한 간 손상 예측용 바이오마커 및 그 예측방법
US20090226933A1 (en) Quantification of fusion proteins and their activity from chromosomal translocation
CN112639475A (zh) Dlbcl的预后指数中的胸苷激酶(tk-1)
JP6195716B2 (ja) 抗癌剤耐性診断マーカー
WO2025121385A1 (ja) Ｔ細胞関連疾患の病態、予後及び治療効果の予測技術
WO2010062705A1 (en) Cancer diagnosis using ki-67
KR20180099722A (ko) 예측 방법 및 상기 방법에 유용한 키트

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170130

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20171102

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180405

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20180515

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180809